|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-3-31
|
|
pubmed:abstractText |
Patients with malignancy have a 4-fold increase in the risk of developing a venous thrombosis and a 3-fold increase in risk of bleeding. Both low-molecular-weight-heparin (LMWH) and vitamin K antagonists (VKA) have been used for treatment of cancer-associated thrombosis. However, the best anticoagulation approach remains a matter of debate.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0049-3848
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
123
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
837-44
|
|
pubmed:meshHeading |
pubmed-meshheading:18977517-Adult,
pubmed-meshheading:18977517-Fibrinolytic Agents,
pubmed-meshheading:18977517-Hemorrhage,
pubmed-meshheading:18977517-Heparin, Low-Molecular-Weight,
pubmed-meshheading:18977517-Humans,
pubmed-meshheading:18977517-Neoplasms,
pubmed-meshheading:18977517-Randomized Controlled Trials as Topic,
pubmed-meshheading:18977517-Recurrence,
pubmed-meshheading:18977517-Risk Factors,
pubmed-meshheading:18977517-Treatment Outcome,
pubmed-meshheading:18977517-Venous Thromboembolism,
pubmed-meshheading:18977517-Vitamin K
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.
|
|
pubmed:affiliation |
University of Ottawa, Ottawa, Ontario, Canada. mlouzada@ohri.ca
|
|
pubmed:publicationType |
Journal Article,
Meta-Analysis
|
